Kornimate/medical-research-clean huggingface dataset:
dialyzing wisely - improving the delivery of acute renal replacement therapy to albertans

Conditions: Acute Renal Injury

Summary: implementation of an evidence-based and best practices acute rrt pathway aiming to decrease acute rrt program and healthcare systems costs while improving important patient-reported outcomes.

providing acute dialysis to critically ill patients in icu settings is resource and cost intensive. the daily costs of acute dialysis can range from $528/day for intermittent hemodialysis to $865/day for continuous renal replacement therapy. providing acute dialysis in icu settings requires a specialized team of nurses, educators, physicians and stakeholders to ensure its safe and effective prescription and delivery. acute dialysis is typically delivered to some of the most acutely ill patients admitted to the icu to support organ function and sustain life. at present, there is not a standardized approach to the prescription and delivery of acute dialysis therapy in icus across alberta. the dialyzing wisely program will implement a standardized approach to the delivery of best practices for acute dialysis therapy to all patients who receive treatment across icus in alberta.

Eligibility criteria:
inclusion criteria: patient in one of 15 adult and 3 pediatric intensive care units in alberta receive acute rrt as part of their usual clinical care during the intervention period exclusion criteria: * none

Keywords: evidence based care pathway, critical care medicine quality improvement acute renal replacement therapy
gait modification and knee joint load

Conditions: Knee Osteoarthritis

Summary: this pilot study aims to assess the effect of a 6-week individualized gait retraining program on knee load and symptoms in persons with knee osteoarthritis (oa).

this study aims to pilot-test an individualized gait retraining intervention to reduce knee load, guided by real-time visual feedback of the external knee adduction moment (kam), a commonly used determinant for medial tibiofemoral (tf) joint load, during walking. our central hypothesis is that individuals with predominantly medial tf oa can adapt their gait patterns to lower kam during walking; consequently, reduce knee load and pain.

Eligibility criteria:
inclusion criteria: * people with radiographic tf oa fulfilling american college of rheumatology classification criteria * reporting average knee pain on walking \> 3 on an 11-point scale (0-10) in at least one knee * pain or tenderness predominantly located on the medial knee. exclusion criteria: * medial tf joint space width greater than lateral * kellgren/lawrence (k/l) grade 4 * knee surgery or intra-articular corticosteroid injection in the past 6 months * uncomfortable walking on treadmill for 20 minutes * unable to walk without a walking aide * inflammatory arthritis * other musculoskeletal or neurological disorders that affect gait patterns * currently receiving physical therapy
a study of fluzoparib（shr-3162）in brca1/2-mutant relapsed ovarian cancer

Conditions: Ovarian Cancer

Summary: this is a multicenter， open-label study to evluate the efficacy and safety of a novel parp 1/2 inhibitor fluzoparib （shr-3162）in brca1/2-mutant relapsed ovarian cancer.

fluzoparib (shr-3162) is an orally available, small molecule inhibitor of poly-adenosine diphosphate \[adp\] ribose polymerase (parp) 1/2 being developed for treatment of brca1/2-mutant solid tumor. the tolerability, safety and pk of fluzoparib has been evaluated in phase 1 study. an oral formulation is the focus of current development efforts.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of high grade serous or grade 2/3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer； * confirmed documented brca1/2 mutation; * received 2\~4 prior chemotherapy regimens. non-chemotherapy regimens and maintenance therapies administered as single agent treatment will not count as a chemotherapy regimen； * relapsed/progressive disease as confirmed by radiologic assessment； * have measurable disease as defined by recist v1.1. exclusion criteria: * any previous treatment with a parp inhibitor; * patient with any other malignancy which has been active or treated within the previous 5 years; * patients with symptomatic uncontrolled brain metastases; * patients unable to swallow orally administered medication.
bi-axial rotating magnetic field therapy in refractory neuropathic foot pain secondary to diabetic peripheral neuropathy

Conditions: Diabetic Neuropathies

Summary: the researchers will study the application of a commercial pulsed magnetic stimulating device to the feet of patients with moderate-severe foot pain secondary to diabetic peripheral neuropathy (dpn).


Eligibility criteria:
inclusion criteria: * dpn stage 2 and 3; symptomatic \> 6 months exclusion criteria: * pacemaker in patient or mate

Keywords: pulsed magnetic field therapy diabetic peripheral neuropathy neuromodulation diabetic peripheral neuropathic pain sleep benefit diabetic peripheral neuropathic functioning
intraoperative sublingual sufentanil for acute pain in the ambulatory surgery center

Conditions: Pain; Pain, Acute; Anesthesia

Summary: the purpose of this study is to determine if a single dose of sublingual sufentanil given 15-30 minutes prior to wake up is efficacious at reducing recovery room time.

this is a level i randomized prospective outcomes study comparing two groups of patients. within 15-30 minutes of planned wake-up group 1 will receive 30 mcg of sublingual sufentanil and group 2 will not receive sublingual sufentanil.

Eligibility criteria:
inclusion criteria: - adult patients undergoing outpatient ambulatory surgery undergoing general anesthesia for orthopedic surgery exclusion criteria: * non-english speaking patients * patients who have allergy or intolerance to the study drugs or derivatives
an extension study of jr-141 in patients with mucopolysaccharidosis type ii

Conditions: Mucopolysaccharidosis II

Summary: multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the mps ii.


Eligibility criteria:
inclusion criteria: 1. a patient who participated in the preceding study jr-141-301 and completed the week 52 visit, and has no safety concerns to enter this study in the opinion of the investigator or subinvestigator. 2. a patient capable of providing written informed consent in person (however, this is not required for patients aged younger than 20 years at the time of consent or patients with intellectual disability associated with mps ii whose willingness cannot be verified.) 3. for patients aged younger than 20 years at the time of consent or patients with intellectual disability associated with mps ii whose willingness cannot be verified, written consent must be obtained from the legally acceptable representative. (wherever possible, written consent of the patient should be obtained.) 4. male patient whose partner is of child-bearing potential and agrees to use a medically accepted, highly effective method of contraception. exclusion criteria: 1. a patient who used any concomitant medication or therapy that could affect study assessments in the opinion of the investigator or subinvestigator. 2. a patient with a history of serious drug allergy or hypersensitivity that precludes participation in this study in the opinion of the investigator or subinvestigator. 3. a patient judged to be ineligible by the investigator or subinvestigator for other reasons.
a study to evaluate long-term safety of vumerity and tecfidera in participants with multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: the primary objective of the study is to estimate the incidence rate of serious adverse events (saes), including but not limited to malignancies and serious and opportunistic infections, among participants with ms treated with vumerity, tecfidera, other selected disease modifying therapies (dmts \[teriflunomide, beta interferons, or glatiramer acetate\]), or vumerity after switching from tecfidera. the secondary objective of the study is to compare the incidence rate of saes, including but not limited to malignancies and serious and opportunistic infections, among ms participants treated with vumerity, tecfidera, and vumerity after switching from tecfidera with the incidence rate of ms participants treated with other selected dmts (teriflunomide, beta-interferons, or glatiramer acetate), if the sample size allows.


Eligibility criteria:
key inclusion criteria: - participants with ms treated with at least 1 dose of vumerity, tecfidera, or other selected dmts (teriflunomide, beta-interferons, or glatiramer acetate), and whose data are captured in the bmsd network will be included in the study. key exclusion criteria: - none note: other protocol defined inclusion/exclusion criteria may apply
non-interventional study of novoseven® used as on-demand treatment of bleeds in patients with haemophilia a and b with inhibitors

Conditions: Congenital Bleeding Disorder; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors

Summary: this study is conducted in japan. the aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (novoseven®) and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.


Eligibility criteria:
inclusion criteria: * treated with eptacog alpha (novoseven®) exclusion criteria: * investigator decision to measure for antibody as unnecessary medical testing
characterization of immune cells and their secreted cytokines in endometriosis patients

Conditions: Endometriosis

Summary: the eumetriosis project aims to address the most important unmet needs of endometriosis sufferers to advance patient care. the objectives cover all main aspects of disease management, including elucidating the pathogenesis, diagnosing the condition promptly and efficiently, facilitating care by implementing self-management strategies, raising awareness and promoting policy changes. the objectives comprise individual yet intersecting pieces of a puzzle which, when positioned correctly, can immensely improve disease perception and understanding to enhance patient care. the project will prioritise the needs and wants of modern-day patients, focused on providing easily accessible and noninvasive therapeutic options. combining all these elements in a well-coordinated project is pivotal to relieving the heavy burden endometriosis places on european society as a whole.

eumetriosis will generate new knowledge in the field of endometriosis, its drivers and consequences, as well as biological determinants, which will result in a better understanding of endometriosis pathogenesis and the factors involved. specifically, the project will assess the role of the immune cells, diet, cognitive behaviour and other related factors in disease pathogenesis, and develop strategies on how to alleviate endometriosis-associated pain, enhance quality of life and improve outcomes for patients. the knowledge base (like the association between nutrition, epigenetics, the microbiome and endometriosis) and methodologies generated within the project will drive the fields of gynaecology, primary care, pain medicine, urology and gastroenterology forward. finally, through the collection of evidence for effective self-management strategies, the project will pave the path for more patient-tailored health policies. the project aims to link different stakeholder groups involved in this field, like clinicians, patients, healthcare insurers/payers and other researchers in women's health. with this multidisciplinary consortium, eumetriosis will maximise its impact by creating therapeutic and diagnostic endometriosis solutions best suited to real-world applications, with a clear strategy for implementation.

Eligibility criteria:
inclusion criteria: * women with a clinical and/or ultrasound diagnosis of endometriosis who are candidates for surgery * age between 18 and 50 years * pre-menopausal status * experiencing regular menstruation * willing to collect menstrual effluent * signature of informed consent to the study exclusion criteria: * age below 18 years * post-menopausal status * presence of crohn's disease * presence of ulcerative colitis * presence of short bowel syndrome or another chronic inflammatory disease * use immunosuppressive medication * receiving contraceptive hormone therapy * pregnant * presence/history of malignancy

Keywords: endometriosis dermoid cyst immune system
narcolepsy - new potential treatment

Conditions: Narcolepsy

Summary: the overall aim of the study is to investigate the effect of a new, non-pharmacological method that may alleviate the symptoms of narcolepsy and thereby lead to a reduction in the use of medications with potentially serious side effects in patients with this disease.


Eligibility criteria:
inclusion criteria: * signed informed consent * diagnosed with narcolepsy (diagnose code g47.4) * 16 - 60 years of age * mslt has shown hypersomnia (sleeping latency \< 8 min) \& 1 episode rem * hla-type associated with increased occurrence of narcolepsy exclusion criteria: * reduced cognitive function * other relevant organ disease (that could affect the study results or put the patient at risk) * ongoing bacterial infection in the nose * comorbidity that can increase the risk of bleeding * has received treatment with an implantable stimulator or other implantable product in the head and / or in the neck * known pronounced septal deviation * known allergy to polyvinylchloride or medicinal liquid paraffin * women not using adequate contraceptives * participated in a clinical investigational drug trial within the previous 30 days
cardiovascular analysis of pem

Conditions: Myalgic Encephalomyelitis; Chronic Fatigue Syndrome

Summary: the purpose of this study is to examine cardiopulmonary function in chronic fatigue syndrome (cfs) patients and determine how it relates to the common symptom of post-exertional malaise (pem). subjects will complete a maximal exercise test on 2 subsequent days. total blood volume will be measured prior to each exercise test, and patient with hypovolemia on day 1, will be randomized to either a saline or sham infusion prior to the 2nd exercise test. a total of 80 cfs patients will be enrolled.


Eligibility criteria:
inclusion criteria: * ages 25 to 60 * meet the 2015 iom case definition for me/cfs exclusion criteria: * patients with a medical cause for their fatigue * patients taking medications that would dampen cardiac response to exercise * patients with psychotic illness, bipolar disorder, or current major depressive disorder * patients with a history of anorexia or bulimia within 5 years of intake * patients with a history of alcohol or drug abuse within 2 years of intake
hypnofertility for women undergoing in vitro fertilization (hwuivf)

Conditions: Infertility Unexplained; Fertility Disorders

Summary: this randomized controlled study aimed to specify whether the interventions based on hypnofertility would lead to increased fertility preparedness and pregnancy outcomes, decreased cortisol levels of women undergoing in vitro fertilization (ivf) treatment.

objective: to specify whether the interventions based on hypnofertility would lead to increased fertility preparedness and pregnancy outcomes, decreased cortisol levels of women undergoing in vitro fertilization (ivf) treatment. design: randomized, controlled, prospective study. setting: university hospital fertility center in izmir. patients: sixty-one women with unexplained infertility undergoing ivf treatment. interventions: interventions based on hypnofertility including affirmations, visualization, dreaming and relaxation from the first day of treatment to the day of pregnancy test. main outcome measures: fertility preparedness and cortisol levels (primary outcomes), pregnancy rate (secondary outcome).

Eligibility criteria:
inclusion criteria: * primary infertility, * unexplained infertility, * going to undergo ivf treatment, * fresh embryos, * under 39 years of age * having a smart phone exclusion criteria: * participated in any program to reduce stress * having any psychiatric disorder

Keywords: hypnofertility fertility preparedness cortisol level pregnancy outcome
a comparison of a new drug to treat overactive bladder vs. placebo

Conditions: Overactive Bladder

Summary: a new drug for overactive bladder is compared to placebo to determine if it is safe and effective. the study lasts approximately 12 weeks.


Eligibility criteria:
inclusion criteria: * females and males, 18 years of older with overactive bladder symptoms exclusion criteria: * treatable conditions that may cause urinary incontinence * medical conditions in which it would be unsafe to use an anti-cholinergic agent. * the use of concomitant drugs that would confound the efficacy evaluation. * the use of concomitant drugs that would be unsafe with an anti-cholinergic agent.

Keywords: oab, anticholineric, oxybutynin, urge urinary incontinence
value of patch testing in direct diet therapy for eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: this study is being done to see if allergy patch testing (apt) can help predict effective dietary therapy in patients with eosinophilic esophagitis.

patients are referred to mayo clinic rochester with an establish diagnosis of eoe and are nonresponsive to proton pump inhibitor (ppi) medical therapy. eligible patients will then meet with one of three investigators complete the mayo dysphagia questionaire-30 day (mdq-30) following which a standardized allergy patch testing (apt) will be conducted. thereafter, a standard clinically indicated six food elimination diet treatment completed. patients will follow up with one of three investigators following the elimination diet who will be blinded to the results of the apt. during this visit responders and nonresponders will be identified and nonresponders will complete a directed elimination diet based on apt results.

Eligibility criteria:
inclusion criteria: * adults ages 18-90 * patients with eoe, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field (eos per hpf) on index esophageal biopsy * persistent symptoms and/or greater than or equal to 10 eos per hpf on esophageal biopsy after at least 8 weeks of twice daily ppi therapy exclusion criteria: * patients with conditions known to be associated with esophageal eosinophilia, including crohn's disease, churg-strauss, achalasia, and hypereosinophilic syndrome * topical swallowed steroids within 8 weeks of study enrollment * dermatologic conditions precluding application of finn chambers to the skin for apt * inability to read due to: blindness, cognitive dysfunction, or english language illiteracy

Keywords: allergy patch testing eosinophilic esophagitis eoe
palliative care yields cancer wellbeing support

Conditions: Cancer

Summary: the goal of this study is to evaluate the effectiveness of a programme for transitional palliative cancer care (pal-cycles) in seven countries (the netherlands, germany, united kingdom, hungary, poland, romania and portugal) and its consequent effects on the number of readmissions into hospital. the main hypothesis for the study is: that fewer people in the intervention arm of the study will require hospital re admission than those having usual care. participants will be asked to fill in questionnaires regarding their quality of care and quality of life.

the study described in this protocol, a stepped wedge clinical trial, is part of a larger research project named: the palliative care yields cancer wellbeing support programme (pal-cycles). the aim is to test and evaluate the implementation of the pal-cycles intervention, by implementing it in 14 care setting across seven european countries (the netherlands, germany, united kingdom, poland, hungary, romania and portugal.) the primary focus of the evaluation will be on measuring the effect of the pal cycles intervention using the number of patients being readmitted into hospital after they had transferred to community care in comparison with patients receiving usual care. additional relevant outcomes will also be gathered and analysed such as: the patient's quality of life, the experience from the family carer and the experience from the healthcare professional. finally, an economic analysis will be embedded in the stepped wedge design. the goals of the overarching research project are as follows: 1. to develop, implement and evaluate a transitional palliative cancer care intervention, with an intervention (the pal-cycles intervention) that aims for a smooth transition from the hospital to community-based care in the final months of life. 2. adaptation of the transitional palliative cancer care intervention for patients with advanced cancer for its implementation in seven european countries within the project. 3. training of oncologists in identifying patients with palliative care needs, establishing collaboratively comprehensive treatment and care plans, delivering patient-centred communication around discharge planning, advance care planning, and end-of-life care. 4. a clinical trial using a stepped wedge design will be implemented in fourteen care settingsacross seven european countries. 5. an implementation support intervention will guide the implementation of the clinical trial in all settings and will investigate barriers and opportunities for implementation and provide tailormade solutions where needed. 6. dissemination of project results.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or above * patients diagnosed with advanced cancer * patients that are expected to develop or already may have palliative care needs * patients who are in transition from curative (hospital) to palliative care (community care) exclusion criteria: * people with cancer unable or unwilling to provide consent to participate in the study

Keywords: palliative care transitional care end of life care